Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.69 |
| ▸ | CA1 | P00915 | 3/20 | 0.69 |
| ▸ | CA2 | P00918 | 2/20 | 0.69 |
| ▸ | CA7 | P43166 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA6 | P23280 | 1/20 | 0.69 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mebutizide SCHEMBL29357329 | 1.00 | LMNA (0.69) | LMNACA1CA2CA7HTT | |
| Mebutizide SCHEMBL13725122 | 0.88 | LMNA (0.64) | LMNACA1CA2CA7HTT | |
| SCHEMBL30561865 | 0.86 | LMNA (0.79) | LMNACA1CA2CA7HTT | |
| SCHEMBL29132639 | 0.86 | LMNA (0.79) | LMNACA1CA2CA7HTT | |
| Cyclothiazide SCHEMBL28086372 | 0.85 | LMNA (0.76) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL29356280 | 0.82 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL25493 | 0.82 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| Trichlormethiazide SCHEMBL25492 | 0.82 | LMNA (1.00) | LMNACA1CA2CA7HTT | |
| Bemetizide SCHEMBL564338 | 0.79 | LMNA (0.68) | LMNACA1CA2CA7HTT | |
| Ethiazide SCHEMBL122238 | 0.79 | TDP1 (1.00) | LMNACA1CA2CA7HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 369 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-12203941-B2 | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | ASTUTE MEDICAL, INC. (US) | 2025-01-21 | — | — | US | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| CN-116603066-A | Composition for treating hypertension | 乔治全球健康研究院 | 2023-08-18 | — | — | CN | claimed |
| US-20230134747-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2023-05-04 | — | — | US | claimed |
| EP-4121034-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Stalicla S.A. (CH) | 2023-01-25 | — | — | EP | claimed |
| WO-2021186074-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2021-09-23 | — | — | WO | claimed |
| EP-3881842-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Stalicla S.A. (CH) | 2021-09-22 | — | — | EP | claimed |
| EP-3485908-B1 | THERAPEUTIC COMBINATION AND USE OF DLL4 ANTAGONIST ANTIBODIES AND ANTI-HYPERTENSIVE AGENTS | MEREO BIOPHARMA 5 INC (US) | 2021-08-18 | — | — | EP | claimed |
| US-20200271669-A1 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | ASTUTE MEDICAL, INC. (US) | 2020-08-27 | — | — | US | claimed |
| WO-2010059967-A2 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | claimed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20040176373-A1 | 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and an agent used in the treatment of the cardiac conditions associated with diabetes mellitus | SMITHKLINE BEECHAM P.L.C. | 2004-09-09 | — | — | US | claimed |
| US-20030060489-A1 | Novel method of treatment | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-27 | — | — | US | claimed |
| EP-1261373-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SmithKline Beecham plc (GB) | 2002-12-04 | — | — | EP | claimed |
| WO-2001047509-A2 | COMPOSITION FOR THE TREATMENT DIABETES MELLITUS CONTAINING AN INSULINE SENSITIZER AND AGENT USED IN THE TREATMENT OF CARDIAC CONDITIONS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-07-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | REN, ACE, AGTR2 | LMNA 2125/4885CA1 749/4885CA2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.